Tirzepatide ELISA Kit

Sample

Serum, Plasma

Species Reactivity

Universal

Detection Method

cELISA

Intended Use

The kit is a competitive inhibition enzyme immunoassay technique for the in vitro quantitative measurement of Tirzepatide in serum and plasma.

Contents of Kit

1. Wash Buffer (50 ml, 20 × concentrate)
2. 96-well immunoplate with plate sealer
3. Antiserum (lyophilized powder)
4. Standard (500 ng, lyophilized powder)
5. Biotinylated tracer (lyophilized powder)
6. Streptavidin-HRP (12 ml, ready to use)
7. Sample Diluent (50 ml, ready to use)
8. TMB substrate (2 × 6 ml, ready to use)
9. Stop solution (7 ml, ready to use)
10. Kit Datasheet/Protocol Insert

Storage

All the components should be stored in the refrigerator (4-8°C) also up to 18 months after you receive the kit. Long term storage, improper storage conditions and large temperature fluctuation cycles may cause precipitates in the TMB solution. These precipitates should not affect the assay noticeably. Nevertheless, if you observe such precipitates, we recommend to avoid them by allowing them to sink to the bottom.

Performance Characteristics

Average IC50: 6.7 ng/ml
Precision: < 15%

Detection Range

0-500 ng/ml

Sensitivity

Blank plasma samples were repeatedly tested to evaluate the analytical sensitivity of the assay based on the background signal in blank matrix. The sensitivity of this kit was determined to be 0.63 ng/mL. With the recommended minimum required dilution of MRD = 5, the corresponding sensitivity in whole plasma is 3.15 ng/mL.


Response curves under different plasma percentages
Response curves under different plasma percentages are provided for reference. The data indicate that plasma concentration may affect curve shape and signal level. If users intend to modify the sample dilution factor, preliminary verification with their own sample matrix is recommended.

General Description

Tirzepatide is a therapeutically effective analog of glucagon-like peptide-1 (GLP-1). GLP-1 is an incretin hormone with important effects on glycemic control and body weight regulation, particularly relevant in people with type 2 diabetes (T2D).
This ELISA was developed with serum from rabbits immunized with Tirzepatide coupled to a carrier protein.
Immunogen: Synthetic peptide Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-C20-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 coupled to carrier protein.

Standard Curve